2021 American Transplant Congress
Hospitalization in the First Year After Kidney Transplantation: Analyses to Identify Common Predictors of Risk Across Recipient Sensitization Groups
University of Florida, Gainesville, FL
*Purpose: We investigated the risk of hospitalization associated with baseline risk factors in adult deceased donor (DD) kidney transplant (KT) recipients (KTRs) stratified into calculated…2021 American Transplant Congress
Dual Liver and Kidney Donors, What Makes Them Decide to Do It?
Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: There is incongruity between the transplant waiting list and the number of deceased donors available, therefore there is an enduring challenge to increase the…2021 American Transplant Congress
Characterisation of Distinct Graft Infiltrates Following Cellular Therapy in Kidney Transplant Recipients
*Purpose: Cellular therapy is an emerging treatment in the field of clinical transplantation with the potential to improve both short and long-term transplant outcomes. We…2021 American Transplant Congress
The Impact of 4-weeks of Supervised Exercise on Frailty and Lower Extremity (LE) Function in Patients with Advanced Chronic Kidney Disease (CKD)
*Purpose: Although frailty is a modifiable risk factor for morbidity and mortality among kidney transplant (KT) candidates, the optimal duration of effective prehabilitation interventions is…2021 American Transplant Congress
Development and Validation of a Novel Peripheral Blood Based Gene Signature for Acute Rejection Following Renal Transplantation
Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
*Purpose: The aim of this study is to utilize advanced machine learning methods to construct a peripheral blood-based gene signature for acute rejection following kidney…2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…2021 American Transplant Congress
Higher Number of Tacrolimus Dose Adjustments and Trough Level Measurements in Kidney Transplant Recipients with CYP3A5*1 Alleles
*Purpose: Tacrolimus (TAC) metabolism is dependent on the functional status of the cytochrome P450 family enzyme CYP3A5 which has three common loss of function (LoF)…2021 American Transplant Congress
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
*Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…2021 American Transplant Congress
Impact of a Latinx Kidney Transplant Clinic
Abdominal Transplant Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC
*Purpose: To evaluate the impact of a Latinx clinic in our institution. With a growing increase of end stage renal disease (ESRD)in the Latino population…2021 American Transplant Congress
Novel Mixed Lymphocyte Reaction Monitoring System That Predicts Chronic Antibody- Mediated Rejection in Kidney Transplant Recipients
*Purpose: Chronic active antibody-mediated rejection (CAAMR) induced by de novo donor-specific antibodies (DSA) is the main cause of graft loss in the long-term. Currently, there…
- « Previous Page
- 1
- …
- 88
- 89
- 90
- 91
- 92
- …
- 531
- Next Page »